{Reference Type}: Practice Guideline
{Title}: Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation.
{Author}: Ponce DM;Politikos I;Alousi A;Carpenter PA;Milano F;MacMillan ML;Barker JN;Horwitz ME; ;
{Journal}: Transplant Cell Ther
{Volume}: 27
{Issue}: 7
{Year}: 07 2021
暂无{DOI}: 10.1016/j.jtct.2021.03.012
{Abstract}: The incidence of graft-versus-host disease (GVHD) after cord blood (CB) transplantation (CBT) is lower than expected given the marked degree of human leukocyte antigen (HLA)-mismatch of CB grafts. While the exact mechanism that underlies this biology remains unclear, it is hypothesized to be due to the low number of mostly immature T-cells infused as part of the graft1,2, and increased tolerance of CB-derived lymphocytes induced by the state of pregnancy. Nevertheless, acute GVHD (aGVHD) is a significant complication of CBT. In contrast, the incidence of chronic GVHD (cGVHD) following CBT is lower than what is observed following matched related or unrelated donor HSC transplantation (HSCT)3-6. This review outlines the guidelines for the prevention and management of acute and chronic GVHD following CBT.